Thank you for Subscribing to Life Science Review Weekly Brief
×
Life Science Review Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review
Top 5 Biotech Startups In UK - 2021
With the soaring importance of biotechnology and life sciences innovations, the UK biotech and life science sector has witnessed significant surges in investments in the present year. A record £3bn has been raised by this sector in the very first three quarters of 2021. This rising trend in investments has led to more funding dedicated towards start-ups, where a total of £576m was raised in the latest quarter of 2021.
The biotech industry today is benefitting immensely from advanced computing technologies such as machine learning and artificial intelligence that is allowing companies to expand the scope and scale of their research. This capability helps improve efficiency in the manufacturing process, which reduces the time taken for biotech companies to introduce newer products to the market. Besides, the evolution of cloud computing technology has eliminated a barrier for multiple innovations in the biotech space. The capability to run applications through the cloud enables companies to store and analyze data without investing in buying expensive computer hardware. These benefit earlystage start-ups that try to restrict operating expenses as much as possible; that said, these very benefits empower larger companies as they makes it easier and cheaper to allocate resources for new projects. Besides, there has been an increased stakeholder collaboration with emerging cloud computing technologies, which support communication, data sharing, and virtual meetings, all of which enable groups to work together irrespective of where they are located. Biotech start-ups have further driven enhancements of clinical trials, eliminating the manual processes with trial participants going to clinics in-person and receive treatments and recording side effects on paper. Drugmakers are also required to invest heavily in marketing resources to recruit the most suitable patients for rare conditions. With the evolution of biotech today, clinical trials have been digitized efficiently, allowing the biotech companies to test treatments on more patients in lesser time.
These springing trends in the biotech space indicate that biotech’s professionals require substantial business skills that are critical for efficiently managing research projects or technical teams, while technology experts can add real-time analysis to breakthroughs in research and development. Against this backdrop, Life Science Review has compiled its latest edition to bring to light the top-in-class biotech startups to help organizations find their right partners and leverage the benefits of sophisticated biotech solutions and services.
Life Science Review presents to you “Top 5 BioTech Startups in UK - 2021.”
Nominate a Company
Our subscribers nominate the companies with whom they have collaborated and gotten results. If you think there is a company that deserves to be on our upcoming prestigious annual list of Top 5 Biotech Startups In UK , please write to us about them and the reasons you think they need to be on the list
-
Aurum Biosciences
Aurum Biosciences Ltd is a clinical-stage biopharmaceutical company developing novel oxygen carriers for therapeutics and diagnostics, initially for acute ischemic stroke (AIS). The company has completed the pre-clinical development of AIS and granted the initial clinical studies in acute stroke patients. Aurum is presently focusing on developing pipeline indications focused on inflammatory conditions and oncology. The company is also developing a novel molecule that carries and delivers oxygen-independent of hemoglobin. Although the molecule can be utilized in multiple indications where oxygen is required, Aurum has selected stroke as its first therapeutic target.
-
Freeline
Freeline aims to deliver one-time gene therapy treatments that provide functional cures through permanently sustained physiological protein levels, leveraging the high expression enabled by our proprietary gene therapy platform. Freeline is a clinical-stage, fully integrated, next-generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. The company is headquartered in the UK and also has operations in Germany and the US. Freeline was founded in 2015 and built upon the pioneering work by our Clinical and Scientific Advisor and Director, Professor Amit Nathwani, Professor of Haematology at UCL.
-
Grey Wolf Therapeutics
Grey Wolf is a preclinical stage company executing on multiple programs focused on harnessing the potential of targeting ERAP as a differentiated and innovative approach to modulate tumor visibility in immuno-oncology. The company is a UK-based biotechnology company focused on developing novel immuno-oncology agents. Grey Wolf was founded in 2017 by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals, and Peter Joyce (CEO), former Project Leader at Vertex Pharmaceuticals. Grey Wolf is currently delivering first-in-class clinical candidates against strongly validated targets.
-
GyreOx
GyreOx offers rapid production of designed libraries of Gyrocycle™, highly modified macrocyclic peptides to hit ‘undruggable’ targets. The company has developed a pipeline to design and rapidly generate focused libraries of molecules that can hit previously undruggable targets. Its combination of computational design, automation, and unique engineered enzymes allows it to deliver novel drugs in the chemical space beyond the 'rule of 5'. GyreOx is focused on library design that enables better compound-target interaction and the tuning of important drug properties.
-
Mursla
Novel exosome characterization platform ExoPheno™ characterizes disease-specific exosomes in several ways: it quantifies them, measures their relative expression of epitopes, and analyses their cargo. Mursla is on a mission to offer life-saving clinical insights to patients and their medical teams. The company recently was granted a patent for its novel nanoelectronics-based sensitive detection method for exosomes and raised over half a million euros to progress development of its exosome-based novel technology.
